PL3447061T3 - Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu - Google Patents
Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworuInfo
- Publication number
- PL3447061T3 PL3447061T3 PL18178715T PL18178715T PL3447061T3 PL 3447061 T3 PL3447061 T3 PL 3447061T3 PL 18178715 T PL18178715 T PL 18178715T PL 18178715 T PL18178715 T PL 18178715T PL 3447061 T3 PL3447061 T3 PL 3447061T3
- Authority
- PL
- Poland
- Prior art keywords
- deoxyuridine
- derivate
- fluoro
- cancer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1103582.1A GB201103582D0 (enExample) | 2011-03-01 | 2011-03-01 | |
| GBGB1105660.3A GB201105660D0 (en) | 2011-04-01 | 2011-04-01 | Chemical compounds |
| EP16150494.9A EP3031812B1 (en) | 2011-03-01 | 2012-02-29 | Chemical compounds |
| EP18178715.1A EP3447061B1 (en) | 2011-03-01 | 2012-02-29 | Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
| PCT/GB2012/050457 WO2012117246A1 (en) | 2011-03-01 | 2012-02-29 | Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer |
| EP12709146.0A EP2681227B1 (en) | 2011-03-01 | 2012-02-29 | Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3447061T3 true PL3447061T3 (pl) | 2022-01-31 |
Family
ID=45841523
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18178715T PL3447061T3 (pl) | 2011-03-01 | 2012-02-29 | Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu |
| PL16150494T PL3031812T3 (pl) | 2011-03-01 | 2012-02-29 | Związki chemiczne |
| PL12709146T PL2681227T3 (pl) | 2011-03-01 | 2012-02-29 | Amidofosforanowe pochodne 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu raka |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16150494T PL3031812T3 (pl) | 2011-03-01 | 2012-02-29 | Związki chemiczne |
| PL12709146T PL2681227T3 (pl) | 2011-03-01 | 2012-02-29 | Amidofosforanowe pochodne 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu raka |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US8933053B2 (enExample) |
| EP (4) | EP3447061B1 (enExample) |
| JP (1) | JP5978232B2 (enExample) |
| KR (1) | KR101885940B1 (enExample) |
| CN (2) | CN103403013B (enExample) |
| AU (1) | AU2012223012C1 (enExample) |
| BR (1) | BR112013021986B1 (enExample) |
| CA (1) | CA2828326C (enExample) |
| CL (1) | CL2013002517A1 (enExample) |
| CY (2) | CY1117445T1 (enExample) |
| DK (3) | DK2681227T3 (enExample) |
| ES (4) | ES2903097T3 (enExample) |
| HR (2) | HRP20160346T1 (enExample) |
| HU (2) | HUE029022T2 (enExample) |
| IL (1) | IL228169A (enExample) |
| LT (1) | LT3447061T (enExample) |
| MX (1) | MX339822B (enExample) |
| NZ (1) | NZ615270A (enExample) |
| PH (2) | PH12013501723A1 (enExample) |
| PL (3) | PL3447061T3 (enExample) |
| PT (2) | PT3447061T (enExample) |
| RS (2) | RS54776B1 (enExample) |
| RU (1) | RU2614406C2 (enExample) |
| SG (1) | SG192841A1 (enExample) |
| SI (2) | SI2681227T1 (enExample) |
| SM (2) | SMT202100715T1 (enExample) |
| WO (1) | WO2012117246A1 (enExample) |
| ZA (2) | ZA201306468B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| EP3447061B1 (en) | 2011-03-01 | 2021-11-24 | NuCana plc | Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
| AU2013346515B2 (en) | 2012-11-16 | 2017-05-25 | NuCana plc | Process for preparing nucleoside prodrugs |
| WO2015013352A2 (en) * | 2013-07-25 | 2015-01-29 | Patel Hasmukh B | Nucleoside phosphoramidates and phosphoramidites |
| CN104447923B (zh) * | 2013-09-23 | 2018-03-30 | 中国药科大学 | 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途 |
| RU2553996C1 (ru) * | 2013-11-27 | 2015-06-20 | Андрей Александрович Иващенко | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| JP2017516779A (ja) * | 2014-05-28 | 2017-06-22 | アイデニクス・ファーマシューティカルズ・エルエルシー | 癌治療のためのヌクレオシド誘導体 |
| CN105153257B (zh) * | 2014-06-12 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 索非布韦的制备方法 |
| MY183198A (en) | 2014-06-25 | 2021-02-18 | Nucana Biomed Ltd | Gemcitabine prodrugs |
| PL225283B1 (pl) * | 2014-07-24 | 2017-03-31 | Univ Im Adama Mickiewicza W Poznaniu | Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie |
| EA031727B1 (ru) | 2014-11-28 | 2019-02-28 | НУКАНА ПиЭлСи | Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений |
| KR102363946B1 (ko) | 2015-03-06 | 2022-02-17 | 아테아 파마슈티컬즈, 인크. | HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드 |
| CN108368147A (zh) * | 2015-05-27 | 2018-08-03 | 南方研究院 | 用于治疗癌症的核苷酸 |
| MX2018005872A (es) | 2015-11-16 | 2019-05-16 | Ichorion Therapeutics Inc | Profarmacos de acido nucleico. |
| GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| HRP20220278T1 (hr) | 2016-09-07 | 2022-05-13 | Atea Pharmaceuticals, Inc. | 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima |
| CN110087666B (zh) | 2016-11-13 | 2024-04-30 | 想象制药公司 | 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法 |
| CN109863160B (zh) | 2016-12-23 | 2022-06-07 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酸类化合物及其制备方法和用途 |
| RU2644156C1 (ru) * | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| CN111315446A (zh) | 2017-08-08 | 2020-06-19 | 中山大学 | 用于治疗多药耐药性肿瘤的方法和组合物 |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) * | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| CN111836823B (zh) * | 2018-03-09 | 2023-06-30 | 国立研究开发法人科学技术振兴机构 | β修饰磷酸化合物前体、β修饰磷酸化合物、反应阻碍剂和包含这些化合物的医药品以及反应阻碍方法 |
| CN110387226A (zh) * | 2018-04-20 | 2019-10-29 | 天津大学 | 一种用于检测肿瘤的荧光探针及用途 |
| US12221649B2 (en) * | 2018-11-30 | 2025-02-11 | The University Of Tokyo | Fluorescent probe for detecting carboxypeptidase activity |
| GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| CN110840907B (zh) * | 2019-08-16 | 2022-11-25 | 南京医科大学 | 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| CN116368143A (zh) * | 2020-08-31 | 2023-06-30 | 埃莫里大学 | 5'-取代的单磷酸核苷、其前药及其相关用途 |
| EP4630433A1 (en) | 2022-12-07 | 2025-10-15 | NuCana plc | Synthesis of nucleoside derivative nuc-3373 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US1002239A (en) | 1902-04-11 | 1911-09-05 | Stromberg Carlson Telephone | Telephone system. |
| US2945038A (en) | 1956-09-26 | 1960-07-12 | Hoffmann La Roche | 5-fluorocytosine and preparation thereof |
| US3201387A (en) | 1963-09-18 | 1965-08-17 | Heidelberger Charles | 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same |
| US3792039A (en) | 1971-12-27 | 1974-02-12 | Miles Lab | Poly 2'-fluoro-2'-deoxyuridylic acid |
| DD279248A1 (de) | 1989-01-01 | 1990-05-30 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| RU2197964C2 (ru) * | 1995-04-12 | 2003-02-10 | Дзе Проктер Энд Гэмбл Компани | Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций |
| WO1999037753A1 (en) | 1998-01-23 | 1999-07-29 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| CN1390227A (zh) | 1999-07-22 | 2003-01-08 | 新生物生物公司 | 酶催化的治疗活化 |
| DE10109657A1 (de) | 2001-02-28 | 2002-09-05 | Menarini Ricerche Spa | Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin |
| WO2003000713A1 (en) | 2001-06-21 | 2003-01-03 | Glaxo Group Limited | Nucleoside compounds in hcv |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| US8399428B2 (en) | 2004-12-09 | 2013-03-19 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| GB0505781D0 (en) | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| JP2009504704A (ja) | 2005-08-15 | 2009-02-05 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート |
| WO2007056596A2 (en) | 2005-11-09 | 2007-05-18 | Wayne State University | Phosphoramidate derivatives of fau |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| CN101922935B (zh) | 2010-07-16 | 2012-07-18 | 北京大学 | 一种最小互易结构干涉型全光纤陀螺仪 |
| EP2596004B1 (en) | 2010-07-19 | 2014-09-10 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| WO2012048013A2 (en) | 2010-10-06 | 2012-04-12 | Inhibitex, Inc. | Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections |
| WO2012117027A1 (en) | 2011-03-01 | 2012-09-07 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| EP3447061B1 (en) * | 2011-03-01 | 2021-11-24 | NuCana plc | Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
| NO3119794T3 (enExample) | 2014-06-25 | 2018-03-10 | ||
| EA031727B1 (ru) | 2014-11-28 | 2019-02-28 | НУКАНА ПиЭлСи | Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений |
| TR201806642T4 (tr) | 2015-05-14 | 2018-06-21 | NuCana plc | Kanser tedavileri. |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
-
2012
- 2012-02-29 EP EP18178715.1A patent/EP3447061B1/en active Active
- 2012-02-29 RU RU2013143862A patent/RU2614406C2/ru active
- 2012-02-29 SI SI201230488T patent/SI2681227T1/sl unknown
- 2012-02-29 EP EP16150494.9A patent/EP3031812B1/en active Active
- 2012-02-29 NZ NZ615270A patent/NZ615270A/en unknown
- 2012-02-29 MX MX2013009815A patent/MX339822B/es active IP Right Grant
- 2012-02-29 ES ES18178715T patent/ES2903097T3/es active Active
- 2012-02-29 RS RS20160211A patent/RS54776B1/sr unknown
- 2012-02-29 ES ES21209926T patent/ES3039965T3/es active Active
- 2012-02-29 RS RS20211549A patent/RS62721B1/sr unknown
- 2012-02-29 AU AU2012223012A patent/AU2012223012C1/en active Active
- 2012-02-29 PT PT181787151T patent/PT3447061T/pt unknown
- 2012-02-29 ES ES12709146.0T patent/ES2569185T3/es active Active
- 2012-02-29 DK DK12709146.0T patent/DK2681227T3/da active
- 2012-02-29 HR HRP20160346TT patent/HRP20160346T1/hr unknown
- 2012-02-29 DK DK16150494.9T patent/DK3031812T3/en active
- 2012-02-29 SM SM20210715T patent/SMT202100715T1/it unknown
- 2012-02-29 EP EP12709146.0A patent/EP2681227B1/en active Active
- 2012-02-29 US US14/000,682 patent/US8933053B2/en active Active
- 2012-02-29 PL PL18178715T patent/PL3447061T3/pl unknown
- 2012-02-29 SI SI201231972T patent/SI3447061T1/sl unknown
- 2012-02-29 PT PT16150494T patent/PT3031812T/pt unknown
- 2012-02-29 KR KR1020137025749A patent/KR101885940B1/ko active Active
- 2012-02-29 WO PCT/GB2012/050457 patent/WO2012117246A1/en not_active Ceased
- 2012-02-29 HR HRP20211967TT patent/HRP20211967T1/hr unknown
- 2012-02-29 HU HUE12709146A patent/HUE029022T2/en unknown
- 2012-02-29 PL PL16150494T patent/PL3031812T3/pl unknown
- 2012-02-29 HU HUE18178715A patent/HUE060127T2/hu unknown
- 2012-02-29 CN CN201280010761.4A patent/CN103403013B/zh active Active
- 2012-02-29 BR BR112013021986-6A patent/BR112013021986B1/pt active IP Right Grant
- 2012-02-29 PL PL12709146T patent/PL2681227T3/pl unknown
- 2012-02-29 PH PH1/2013/501723A patent/PH12013501723A1/en unknown
- 2012-02-29 LT LTEP18178715.1T patent/LT3447061T/lt unknown
- 2012-02-29 ES ES16150494.9T patent/ES2686219T3/es active Active
- 2012-02-29 EP EP21209926.1A patent/EP4023299B1/en active Active
- 2012-02-29 CA CA2828326A patent/CA2828326C/en active Active
- 2012-02-29 JP JP2013555935A patent/JP5978232B2/ja active Active
- 2012-02-29 DK DK18178715.1T patent/DK3447061T3/da active
- 2012-02-29 CN CN201510329656.2A patent/CN104974206B/zh active Active
- 2012-02-29 SG SG2013062823A patent/SG192841A1/en unknown
-
2013
- 2013-08-28 IL IL228169A patent/IL228169A/en active IP Right Grant
- 2013-08-30 CL CL2013002517A patent/CL2013002517A1/es unknown
- 2013-09-09 ZA ZA2013/06468A patent/ZA201306468B/en unknown
-
2014
- 2014-12-04 US US14/560,097 patent/US9221866B2/en active Active
- 2014-12-09 ZA ZA2014/09013A patent/ZA201409013B/en unknown
-
2015
- 2015-03-05 PH PH12015500485A patent/PH12015500485A1/en unknown
- 2015-11-17 US US14/943,555 patent/US9655915B2/en active Active
-
2016
- 2016-04-27 CY CY20161100360T patent/CY1117445T1/el unknown
- 2016-05-06 SM SM201600132T patent/SMT201600132B/it unknown
-
2017
- 2017-04-18 US US15/489,884 patent/US10022390B2/en active Active
-
2018
- 2018-06-28 US US16/021,103 patent/US10993957B2/en active Active
-
2021
- 2021-04-06 US US17/223,241 patent/US11559542B2/en active Active
- 2021-12-17 CY CY20211101114T patent/CY1124871T1/el unknown
-
2023
- 2023-01-11 US US18/095,937 patent/US11925658B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3447061T3 (pl) | Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu | |
| IL232268A0 (en) | Methods for treating cancers using oral formulations of cytidine analogs | |
| HUE044611T2 (hu) | Gyógyászati készítmény rák kezelésére | |
| PT2824114T (pt) | Composição farmacêutica para o tratamento do cancro | |
| PL3791896T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| EP2894985A4 (en) | PROGRAMMABLE ACTIVE COMPOUND PROFILES OF TUMORED BACTERIA | |
| HUE047198T2 (hu) | Fitokannabinoidok emlõrák kezelésére | |
| PH12014500912A1 (en) | Novel purine derivatives and their use in the treatment of disease | |
| HUE040524T2 (hu) | Mellrák kezelése | |
| HRP20190318T1 (hr) | Farmaceutski ili kozmetički pripravak za liječenje alopecije | |
| IL238107B (en) | Compositions comprising masitinib for use in treatment of cancer in patient subpopulations identified using predictor factors | |
| PL2582366T3 (pl) | Kombinacja farmaceutyczna do leczenia bólu | |
| PL3443957T3 (pl) | Związki i kompozycje stosowane w leczeniu nowotworów | |
| IL240976A0 (en) | A pharmaceutical preparation containing albumin-binding arginine deaminase for targeted cancer therapy | |
| BR112013014076A2 (pt) | métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer | |
| PL2729008T3 (pl) | Systemy, sposoby i formulacje do leczenia raka | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft | |
| EP2931042A4 (en) | ANTHRACYCLINFORMULIERUNGEN | |
| PL2619331T3 (pl) | Sposoby leczenia nowotworu obejmujące ukierunkowanie na nqo1 | |
| UA110131C2 (ru) | ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ | |
| UA117809C2 (uk) | Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку | |
| BR112013030930A2 (pt) | composições farmacêuticas combinadas para o tratamento de tumores | |
| PL3363439T3 (pl) | Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej | |
| SMT201700061B (it) | Vaccino dna di her2 come trattamento aggiuntivo per tumori in animali di compagnia | |
| EP2726505A4 (en) | THERAPEUTIC TARGETING OF FICOLIN-3 |